October 11, 2010
Make way for the future, at least when it comes to stem-cell therapy. An Atlanta hospital treated the first patient Friday in a nationwide clinical trial of a therapy derived from embryonic stem cells. The clinical trial, run by pharmaceutical company Geron Corp., seeks to test whether experimental cells, known as GRNOPC1, are safe for use in humans and whether patients will regain neuromuscular control in their legs and torsos. The Shepherd Center in Atlanta, a rehabilitation hospital that specializes in people who have spinal cord injuries or disease, and Northwestern Medicine in Chicago are currently enrolling patients in the trial.
September 7, 2006 |
Geron Corp. and Advanced Cell Technology Inc. agreed to settle a patent dispute over a pioneering cloning technology that led to the creation of Dolly the sheep. Advanced Cell and the University of Massachusetts agreed to end their appeal and give up certain patents for animal cloning technology while keeping rights to a cloning method for human use, Advanced Cell said. Menlo Park, Calif.-based Geron keeps the rights to use the technology in animal cloning.
July 19, 2005 |
Biotech company Geron Corp. said Monday that it had signed a licensing deal with drug maker Merck & Co. to develop a cancer vaccine that targets an enzyme linked to tumor growth, sending Geron shares up 27%. Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Specific terms were not disclosed.
June 11, 2003 |
Shares in Geron Corp. rose nearly 15% on Tuesday after the small biotech company said it received a patent that could give it an advantage in the race to produce medicines from human embryonic stem cells. The Menlo Park-based firm's shares closed at $7.98, up $1.02, on Nasdaq, after hitting a 52-week high of $9.75 earlier in the day. Embryonic stem cells are formed in the earliest weeks of pregnancy and are capable of turning into any of the 300 cell types in the body.
April 2, 2003 |
Shares of struggling Geron Corp. skyrocketed 28% on Tuesday after it published research indicating that it could produce liver cells from stem cells in a way that may help scientists test drugs for liver toxicity. In the journal Cell Transplantation, the biotech company described how its scientists produce hepatocytes, the basic functional cells of the liver, from human embryonic stem cells. Hepatocytes have multiple characteristics, including the ability to metabolize enzymes.
March 19, 2003 |
The stock price of struggling Geron Corp. skyrocketed Tuesday after the company said its experimental cancer vaccine showed promise in fighting all types of the disease. The money-losing biotechnology company had laid off much of its staff in the last year. Its stock recently had languished below $2 a share. Geron's stock soared $2.47 a share, closing at $4.20 on Nasdaq. Nearly 18 million Geron shares traded hands Tuesday, up from about 113,000 shares on an average trading day.